Disseminated sporotrichosis is a rare, life-threatening form of infection caused by the dimorphic fungus Sporothrix spp. (primarily S. schenckii, S. brasiliensis, S. globosa), occurring predominantly in immunocompromised hosts via hematogenous spread to multiple organ systems including skin, lungs, bones/joints, CNS, and eyes. [1-3] One-year mortality is 17% overall and significantly higher in disseminated disease, with mortality reaching 37% in HIV co-infected patients. [2][4]
1. History
- Subacute-to-chronic onset of multifocal skin lesions (nodules, ulcers, plaques) in non-contiguous distributions — key distinguishing feature from lymphocutaneous form [1][5]
- Exposure history: contact with cats (especially in endemic areas like Brazil), soil, sphagnum moss, rose bushes, hay, or organic debris; occupational exposures (floriculture, agriculture, mining) [3][6]
- Timing: primary inoculation site develops 1–4 weeks post-exposure; dissemination may occur weeks to months later, especially if immunosuppression is present or iatrogenic immunosuppression is initiated [7-8]
- Systemic symptoms: fever, weight loss, malaise — significantly associated with systemic disease (p = .001 and .006, respectively) [9]
- Joint pain/swelling, cough, dyspnea, visual changes, headache, behavioral changes depending on organ involvement [1][10]
- Ask about prior antifungal treatment and response (treatment failure may indicate resistance or dissemination) [11]
2. Alarm Features
- Multifocal skin lesions in non-dermatomal distribution (suggests hematogenous spread) [5][12]
- Fever + weight loss in a patient with known cutaneous sporotrichosis [9]
- Meningeal signs: headache, altered mental status, behavioral changes, visual hallucinations, paraplegia — CNS involvement carries the highest mortality [1][9-10]
- Rapidly progressive lesions despite antifungal therapy [8]
- New pulmonary symptoms (cough, hemoptysis, dyspnea) [1]
- Osteoarticular involvement: multifocal bone pain, joint swelling, osteomyelitis in ≥2 bones [13]
- Ocular involvement: vision changes, eye pain [1]
- Worsening disease after initiation of immunosuppressive therapy (iatrogenic dissemination) [8][14]
3. Medications
- First-line for disseminated disease: Liposomal amphotericin B (L-AmB) 3–5 mg/kg/day IV as induction therapy [5-6]
- Alternative: Amphotericin B deoxycholate (AmB-d) 0.7–1.0 mg/kg/day IV [6]
- Step-down therapy: Itraconazole 200 mg PO twice daily for at least 12 months after clinical response [5-6]
- Monitor itraconazole trough levels (target >0.5 µg/mL) given erratic absorption [5][15]
- Contraindicated/ineffective: Voriconazole and isavuconazole have high MICs against Sporothrix spp. and are not recommended [6]
- Fluconazole has poor activity and should be avoided [11]
- Drug interactions: Itraconazole interacts significantly with tacrolimus, cyclosporine, and multiple ARVs — requires close TDM [15-16]
- In HIV patients: ART should be continued/initiated; monitor for IRIS [15]
4. Diet
- No specific dietary triggers or restrictions for sporotrichosis
- Ensure adequate nutritional support in patients with systemic disease, weight loss, and prolonged hospitalization
- Itraconazole absorption is enhanced with acidic beverages and fatty meals (capsule formulation); solution is taken on an empty stomach
- Avoid grapefruit juice (CYP3A4 interaction with azoles)
5. Review of Systems
- Skin: new nodules, ulcers, or plaques in non-contiguous areas
- Pulmonary: cough (productive or dry), hemoptysis, dyspnea, pleuritic chest pain
- MSK: joint pain/swelling, bone pain, decreased range of motion
- Neuro: headache, confusion, behavioral changes, visual hallucinations, focal deficits, neck stiffness [10]
- Ophthalmologic: vision changes, eye pain, photophobia [1]
- Constitutional: fever, night sweats, weight loss, fatigue [9]
- Mucosal: oral/nasal ulcers [1]
6. Collateral History and Family History
- Cat contact: especially sick or stray cats with skin lesions — major zoonotic vector in endemic areas (Brazil, South America) [3][6]
- Occupational/recreational exposure to soil, plants, organic matter [3]
- HIV status and ART adherence — all HIV-positive patients in one Brazilian cohort developed systemic disease [9]
- Immunosuppressive medications: anti-TNF agents, corticosteroids, transplant immunosuppression [8][14][16]
- Travel to or residence in endemic areas (tropical/subtropical regions, southeastern US, Latin America, East Asia) [2][6]
- Family history is generally not contributory (not a hereditary condition)
7. Risk Factors
- HIV/AIDS (especially CD4 <200 cells/mm³) — strongest risk factor; 69.5% of HIV co-infected patients develop systemic dissemination [4][9]
- Alcohol use — independently associated with systemic disease (p = .009), particularly pulmonary involvement [9]
- Diabetes mellitus — associated with disseminated disease, favoring osteoarticular and ocular involvement [9][12]
- Malignancy/neoplasms (25% of sporotrichosis patients in a global cohort) [2]
- Iatrogenic immunosuppression: anti-TNF therapy, corticosteroids, transplant medications [8][14][16]
- Chronic corticosteroid use
- Residence in or travel to hyperendemic areas (aPR 1.64 for systemic infection) [13]
- Older age [2]
- Hyperferritinemia — associated with higher mortality [2]
8. Differential Diagnosis
- Cutaneous leishmaniasis — similar noduloulcerative lesions; travel history, biopsy with amastigotes
- Nocardiosis — lymphocutaneous spread pattern; partially acid-fast organisms on stain
- Atypical mycobacterial infection (M. marinum, M. kansasii) — aquatic/soil exposure; AFB stain and culture
- Tuberculosis (cutaneous or disseminated) — PPD/IGRA, AFB cultures
- Cryptococcosis — histopathologic mimic; mucicarmine stain, serum/CSF CrAg [17]
- Histoplasmosis (disseminated) — similar systemic presentation in immunocompromised; urine/serum antigen
- Talaromycosis (Talaromyces marneffei) — Southeast Asia; umbilicated papules in HIV patients [17]
- Pyoderma gangrenosum — important clinical mimic; misdiagnosis can lead to iatrogenic immunosuppression and dissemination [8]
- Paracoccidioidomycosis — endemic to Latin America; large yeast with "pilot wheel" morphology
- Blastomycosis — verrucous skin lesions + pulmonary disease; broad-based budding yeast
9. Past Medical History
- HIV/AIDS: CD4 count, viral load, ART regimen and adherence [4][10]
- Prior episodes of sporotrichosis or other endemic mycoses
- Organ transplant history and immunosuppressive regimen [16]
- Autoimmune disease on biologics (especially anti-TNF agents) [14]
- Diabetes mellitus [9][12]
- Chronic lung disease (predisposes to pulmonary sporotrichosis) [18]
- Malignancy and chemotherapy [2]
- Alcohol use disorder [9]
- Prior surgical history (especially if orthopedic — relevant for osteoarticular involvement)
10. Physical Exam
- Skin: Multiple erythematous nodules, papules, plaques, or ulcers in non-contiguous, non-lymphatic distribution — hallmark of hematogenous dissemination [5][12]
- Vitals: Fever (may be low-grade or high), tachycardia; hemodynamic instability in severe cases
- Lymph nodes: Regional lymphadenopathy
- Pulmonary: Crackles, decreased breath sounds, signs of consolidation or cavitation
- MSK: Joint effusions, tenderness, decreased ROM; bony tenderness over affected sites [1][13]
- Neuro: Meningismus, cranial nerve palsies, altered sensorium, focal deficits [10]
- Ophthalmologic: Conjunctival injection, dacryocystitis, chorioretinitis on fundoscopy [1]
- Mucosal: Oral, nasal, or laryngeal ulcers [1]
- Hepatosplenomegaly in severe disseminated cases
11. Lab Studies
- Fungal culture (gold standard): Skin/tissue biopsy, aspirate, sputum, blood, CSF, synovial fluid — inoculate on Sabouraud dextrose agar at room temperature; growth in 1–4 weeks [5-6]
- Histopathology: Suppurative and granulomatous inflammation; PAS and GMS stains may reveal oval-to-cigar-shaped yeast (3–5 µm) with asteroid bodies, though sensitivity is low (~14–51%) [6][19]
- Blood cultures: Obtain in all suspected disseminated cases [16]
- CSF analysis if CNS involvement suspected: Lymphocytic pleocytosis, elevated protein [10]
- CBC: Leukocytosis or leukopenia; may show pancytopenia in severe dissemination
- CMP: Renal and hepatic function (baseline before amphotericin B)
- HIV testing: Mandatory in all cases of disseminated sporotrichosis; if positive, obtain CD4 count and viral load [4][9]
- Inflammatory markers: ESR, CRP, ferritin (hyperferritinemia associated with worse outcomes) [2]
- Itraconazole trough levels during step-down therapy (target >0.5 µg/mL) [15]
- ELISA serology: Good sensitivity (89–90%) and specificity (100%) where available, but limited availability [6]
12. Imaging
- Chest X-ray/CT chest: For pulmonary involvement — may show cavitary lesions, nodules, infiltrates, hilar lymphadenopathy [1]
- MRI brain/spine: If CNS involvement suspected — leptomeningeal enhancement, communicating hydrocephalus, contrast-enhancing granulomas [10]
- X-ray/MRI of affected joints/bones: Osteolytic lesions, periosteal reaction, joint effusions in osteoarticular disease [1][13]
- CT abdomen: Hepatosplenomegaly, visceral abscesses in severe dissemination
- Imaging is not routinely needed for isolated cutaneous disease but is essential in disseminated forms to assess extent of organ involvement [6][16]
- Rhinolaryngoscopy and fundoscopy should be included in the workup of suspected disseminated disease to detect pauci- or asymptomatic mucosal/ocular lesions [16]
13. Special Tests
- Molecular identification: PCR and DNA sequencing for species-level identification (S. brasiliensis vs S. schenckii vs S. globosa) — important for virulence and epidemiologic implications [6][20]
- Antifungal susceptibility testing: Recommended in disseminated/refractory cases; reduced susceptibility to itraconazole has been reported [11][20]
- Latex agglutination test: Previously used for meningeal sporotrichosis but no longer commercially available [6]
- Autofluorescence on HE-stained sections: Emerging diagnostic adjunct under investigation [21]
- Lumbar puncture: Mandatory if any neurologic symptoms — CSF for cell count, protein, glucose, fungal culture, and cytology [10]
- Arthrocentesis: Synovial fluid analysis and culture for suspected osteoarticular involvement
14. ECG
- Not a primary diagnostic tool for sporotrichosis
- Obtain baseline ECG before initiating amphotericin B (monitor for electrolyte-related arrhythmias secondary to hypokalemia and hypomagnesemia)
- Itraconazole carries a negative inotropic effect — ECG monitoring warranted in patients with heart failure or cardiac history
- Itraconazole is contraindicated in patients with ventricular dysfunction (FDA boxed warning)
15. Assessment
Disseminated sporotrichosis is a serious, potentially fatal systemic fungal infection occurring almost exclusively in immunocompromised patients. Key clinical features include:
- Multifocal cutaneous lesions in non-lymphatic distribution (hematogenous spread) [5][12]
- Extracutaneous involvement: pulmonary, osteoarticular, CNS, ocular, mucosal [1]
- Approximately 8% of sporotrichosis cases disseminate; of those, up to 17% develop CNS disease [10]
- One-year mortality is 17% overall; mortality is significantly higher with disseminated disease, older age, neoplasms, and hyperferritinemia [2]
- In HIV co-infection, mortality reaches 37%, and meningeal involvement further increases mortality risk [4][9]
- Atypical presentations (e.g., mimicking pyoderma gangrenosum) can lead to misdiagnosis and iatrogenic worsening [8]
16. Treatment Plan
Initial Stabilization (Induction)
- Liposomal amphotericin B 3–5 mg/kg/day IV — first-line for all disseminated, meningeal, and severe pulmonary disease [5-6]
- Alternative: Amphotericin B deoxycholate 0.7–1.0 mg/kg/day IV [6]
- Duration of induction: typically 2 weeks or until clinical improvement [15]
- Aggressive IV hydration and electrolyte monitoring (K⁺, Mg²⁺) during amphotericin B therapy
- Renal function monitoring (BUN/Cr) at least every other day
Step-Down (Consolidation/Maintenance)
- Itraconazole 200 mg PO twice daily for at least 12 months [5-6]
- Monitor itraconazole trough levels (target >0.5 µg/mL) [15]
- In HIV patients: itraconazole 200 mg PO daily as secondary prophylaxis; can discontinue when CD4 >100 cells/mm³ for ≥6 months on suppressive ART [15]
Adjunctive Measures
- Initiate or optimize ART in HIV patients [15]
- Surgical debridement/excision may be needed for osteoarticular or pulmonary cavitary disease [1][13]
- Reduce or discontinue immunosuppression when possible (e.g., hold anti-TNF agents, consider switching to vedolizumab in IBD patients) [14][16]
- If no response after 15 days of treatment in transplant patients, consider suspension of immunosuppression [16]
Medications to Avoid
- Voriconazole and isavuconazole (high MICs, not effective) [6]
- Fluconazole (poor activity) [11]
17. Disposition
Admission Criteria
- All patients with suspected or confirmed disseminated sporotrichosis require inpatient admission for IV amphotericin B induction [5-6]
- CNS involvement (meningitis, hydrocephalus) — may require ICU-level care and neurosurgical consultation [10]
- Hemodynamic instability, sepsis, or multiorgan involvement
- Severe immunosuppression (e.g., CD4 <100) with systemic symptoms
Observation Indications
Specialist Consultation Triggers
- Infectious disease: All cases of disseminated sporotrichosis
- Neurosurgery: Hydrocephalus or CNS granulomas [10]
- Ophthalmology: Ocular involvement [1]
- Orthopedics: Osteoarticular disease requiring surgical intervention [13]
- Pulmonology: Cavitary or severe pulmonary disease
- Dermatology: Biopsy and management of cutaneous lesions
Discharge Criteria
- Clinical improvement on IV amphotericin B (defervescence, lesion stabilization)
- Tolerating oral itraconazole with confirmed adequate trough levels
- Stable renal function
- Outpatient infectious disease follow-up arranged
18. Follow Up / Return Precautions
Follow-Up Timing
- Infectious disease follow-up within 1–2 weeks of discharge
- Itraconazole trough level check at 2 weeks after initiation, then periodically [15]
- Renal function and electrolytes monitored during and after amphotericin B course
- HIV patients: CD4 and viral load monitoring every 3 months; secondary prophylaxis with itraconazole 200 mg daily until immune reconstitution [15]
- Total treatment duration: minimum 12 months of itraconazole; longer for CNS or osteoarticular disease [1][6]
Return Precautions
- New or worsening skin lesions
- Fever, chills, or night sweats
- Headache, confusion, vision changes, or neck stiffness (concern for CNS involvement)
- Joint pain or swelling
- Cough, hemoptysis, or shortness of breath
- Nausea, vomiting, or inability to take oral medications
Patient Counseling
- Avoid contact with cats (especially stray/sick cats) and soil/organic matter in endemic areas [3][6]
- Medication adherence is critical — premature discontinuation leads to relapse [11][22]
- Expected recovery is prolonged; clinical improvement may take weeks to months
- Report any side effects of itraconazole (GI upset, hepatotoxicity, peripheral edema) or amphotericin B (rigors, renal toxicity)
References
1. Extracutaneous Sporotrichosis. — Ramírez-Soto MC. Clinical Microbiology Reviews. 2025.
2. Extracutaneous Sporotrichosis. — Ramírez-Soto MC. Clinical Microbiology Reviews. 2025.
3. Extracutaneous Sporotrichosis. — Ramírez-Soto MC. Clinical Microbiology Reviews. 2025.
4. Epidemiology and Outcomes of Sporotrichosis: A Descriptive Real-World Analysis From a Global Cohort. — Schapiro S, Pulciano N, Galindo-Ramirez J, et al. Mycoses. 2026.
5. Epidemiology and Outcomes of Sporotrichosis: A Descriptive Real-World Analysis From a Global Cohort. — Schapiro S, Pulciano N, Galindo-Ramirez J, et al. Mycoses. 2026.
6. Sporothrix Schenckii and Sporotrichosis. — Barros MB, de Almeida Paes R, Schubach AO. Clinical Microbiology Reviews. 2011.
7. Sporothrix Schenckii and Sporotrichosis. — Barros MB, de Almeida Paes R, Schubach AO. Clinical Microbiology Reviews. 2011.
8. Sporotrichosis Co-Infection With Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. — Uemura EVG, Rossato L. Mycoses. 2023.
9. Sporotrichosis Co-Infection With Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. — Uemura EVG, Rossato L. Mycoses. 2023.
10. Neglected Endemic Mycoses. — Queiroz-Telles F, Fahal AH, Falci DR, et al. The Lancet. Infectious Diseases. 2017.
11. Neglected Endemic Mycoses. — Queiroz-Telles F, Fahal AH, Falci DR, et al. The Lancet. Infectious Diseases. 2017.
12. Global Guideline for the Diagnosis and Management of the Endemic Mycoses: An Initiative of the European Confederation of Medical Mycology in Cooperation With the International Society for Human and Animal Mycology. — Thompson GR, Le T, Chindamporn A, et al. The Lancet. Infectious Diseases. 2021.
13. Global Guideline for the Diagnosis and Management of the Endemic Mycoses: An Initiative of the European Confederation of Medical Mycology in Cooperation With the International Society for Human and Animal Mycology. — Thompson GR, Le T, Chindamporn A, et al. The Lancet. Infectious Diseases. 2021.
14. Tropical Skin Diseases in Children: A Review— Part I. — García-Romero MT, Lara-Corrales I, Kovarik CL, Pope E, Arenas R. Pediatric Dermatology. 2016.
15. Tropical Skin Diseases in Children: A Review— Part I. — García-Romero MT, Lara-Corrales I, Kovarik CL, Pope E, Arenas R. Pediatric Dermatology. 2016.
16. Disseminated Sporotrichosis Following Iatrogenic Immunosuppression for Suspected Pyoderma Gangrenosum. — White M, Adams L, Phan C, et al. The Lancet. Infectious Diseases. 2019.
17. Disseminated Sporotrichosis Following Iatrogenic Immunosuppression for Suspected Pyoderma Gangrenosum. — White M, Adams L, Phan C, et al. The Lancet. Infectious Diseases. 2019.
18. Clinical Factors Associated With Systemic Sporotrichosis in Brazil. — Magalhães VCR, Colombo SA, Peres NTA, et al. Mycoses. 2024.
19. Clinical Factors Associated With Systemic Sporotrichosis in Brazil. — Magalhães VCR, Colombo SA, Peres NTA, et al. Mycoses. 2024.
20. Teaching NeuroImage: Leptomeningitis With Communicating Hydrocephalus in an Immunocompromised Patient With Disseminated Sporotrichosis. — Taborda MH, Costa FB, Kleinübing JR, et al. Neurology. 2024.
21. Teaching NeuroImage: Leptomeningitis With Communicating Hydrocephalus in an Immunocompromised Patient With Disseminated Sporotrichosis. — Taborda MH, Costa FB, Kleinübing JR, et al. Neurology. 2024.
22. Oral Treatment With 10% Potassium Iodide Solution for Refractory Cutaneous-Disseminated Sporotrichosis in an Immunocompetent Adult: Case Report. — Zhuang K, Dai Y, Zhou Y, et al. Frontiers in Microbiology. 2022.
23. Oral Treatment With 10% Potassium Iodide Solution for Refractory Cutaneous-Disseminated Sporotrichosis in an Immunocompetent Adult: Case Report. — Zhuang K, Dai Y, Zhou Y, et al. Frontiers in Microbiology. 2022.
24. Cutaneous Disseminated Sporotrichosis Associated With Diabetes: A Case Report and Literature Review. — Xia X, Zhi H, Liu Z. PLoS Neglected Tropical Diseases. 2023.
25. Cutaneous Disseminated Sporotrichosis Associated With Diabetes: A Case Report and Literature Review. — Xia X, Zhi H, Liu Z. PLoS Neglected Tropical Diseases. 2023.
26. Differences in Epidemiological and Clinical Findings Between Localized and Systemic Osteoarticular Infection Caused by Sporothrix: A Systematic Review of Individual Participant Data. — Ramírez-Soto MC, Bonifaz A, Tirado-Sánchez A, Song Y, Llanos-Cuentas A. Medical Mycology. 2025.
27. Differences in Epidemiological and Clinical Findings Between Localized and Systemic Osteoarticular Infection Caused by Sporothrix: A Systematic Review of Individual Participant Data. — Ramírez-Soto MC, Bonifaz A, Tirado-Sánchez A, Song Y, Llanos-Cuentas A. Medical Mycology. 2025.
28. Management of Sporotrichosis in Patients With Inflammatory Bowel Disease Using Biological Therapy (Antitumor Necrosis Factor). — Godoy Finger AP, Tavares Ferreira de Oliveira Cruz L, Rosevics L, et al. European Journal of Gastroenterology & Hepatology. 2025.
29. Management of Sporotrichosis in Patients With Inflammatory Bowel Disease Using Biological Therapy (Antitumor Necrosis Factor). — Godoy Finger AP, Tavares Ferreira de Oliveira Cruz L, Rosevics L, et al. European Journal of Gastroenterology & Hepatology. 2025.
30. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
31. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
32. Zoonotic sporotrichosis in renal transplant recipients from Rio de Janeiro, Brazil. — Fichman V, Marques de Macedo P, Francis Saraiva Freitas D, et al. Transplant Infectious Disease : An Official Journal of the Transplantation Society. 2021.
33. Zoonotic sporotrichosis in renal transplant recipients from Rio de Janeiro, Brazil. — Fichman V, Marques de Macedo P, Francis Saraiva Freitas D, et al. Transplant Infectious Disease : An Official Journal of the Transplantation Society. 2021.
34. Cutaneous Sporothrix globosa infection mimicking cryptococcosis in a patient with history of kidney transplant. — Lin EM, Singer H, Telang GH, et al. Journal of Cutaneous Pathology. 2023.
35. Cutaneous Sporothrix globosa infection mimicking cryptococcosis in a patient with history of kidney transplant. — Lin EM, Singer H, Telang GH, et al. Journal of Cutaneous Pathology. 2023.
36. Old and New Therapies for Sporotrichosis. — Kauffman CA. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 1995.
37. Old and New Therapies for Sporotrichosis. — Kauffman CA. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 1995.
38. The Role of Histopathological Examination in the Diagnosis of Cutaneous Sporotrichosis Caused by Sporothrix Globosa: A Retrospective Analysis and Reassessment. — Li L, Li J, Liu Z, Xia X. Mycoses. 2025.
39. The Role of Histopathological Examination in the Diagnosis of Cutaneous Sporotrichosis Caused by Sporothrix Globosa: A Retrospective Analysis and Reassessment. — Li L, Li J, Liu Z, Xia X. Mycoses. 2025.
40. Establishment of Epidemiological Cutoff Values for Clinically Relevant Sporothrix Species Using CLSI-broth Microdilution. — Dos Santos AR, Bonifaz A, Bombassaro A, et al. Antimicrobial Agents and Chemotherapy. 2026.
41. Establishment of Epidemiological Cutoff Values for Clinically Relevant Sporothrix Species Using CLSI-broth Microdilution. — Dos Santos AR, Bonifaz A, Bombassaro A, et al. Antimicrobial Agents and Chemotherapy. 2026.
42. The Diagnostic Value of Autofluorescence in Hematoxylin–Eosin‐Stained Sections for Cutaneous Sporotrichosis. — Wang X, Huang Y. Journal of Cutaneous Pathology. 2026.
43. The Diagnostic Value of Autofluorescence in Hematoxylin–Eosin‐Stained Sections for Cutaneous Sporotrichosis. — Wang X, Huang Y. Journal of Cutaneous Pathology. 2026.
44. Systemic Sporotrichosis Treated With Itraconazole. — Winn RE, Anderson J, Piper J, Aronson NE, Pluss J. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 1993.
45. Systemic Sporotrichosis Treated With Itraconazole. — Winn RE, Anderson J, Piper J, Aronson NE, Pluss J. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 1993.